Dendocrin™
Secondary Hyperparathyroidism (SHPT) in Stage 3 & 4 Chronic Kidney Disease (CKD) with Vitamin D Deficiency
Phase 3Active
Key Facts
Indication
Secondary Hyperparathyroidism (SHPT) in Stage 3 & 4 Chronic Kidney Disease (CKD) with Vitamin D Deficiency
Phase
Phase 3
Status
Active
Company
About Novadiol
Novadiol is a Kansas City-based biopharma company founded in 2012, targeting the large and growing chronic kidney disease market. Its core asset is Dendocrin™, a repurposed drug with a known safety profile, aimed at treating secondary hyperparathyroidism (SHPT) in CKD patients via a 505(b)(2) NDA. The company emphasizes strong worldwide patent protection, low development risk, and an experienced management team as it seeks capital and partnerships to advance its pipeline.
View full company profile